CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: August 15, 2013
Result type: Reports
Project Number: SR0345-000
Product Line: Reimbursement Review

Generic Name: OnabotulinumtoxinA

Brand Name: Botox

Manufacturer: Allergan Inc.

Therapeutic Area: Migraine

Indications: Migraine, chronic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 28, 2014

Recommendation Type: Do not list

Request for Resubmission: Eligible (June 5, 2018)